{
    "info": {
        "nct_id": "NCT01987362",
        "official_title": "A Two-Part, Phase I, Multicenter, Open-Label Study of RO6870810/TEN-010 Given Subcutaneously: Part A: A Dose-Escalation Study in Patients With Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Selected Malignancies",
        "inclusion_criteria": "General:\n\n* Participants with solid tumors must have one or more metastatic tumors evaluable or measurable on radiographic imaging\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (or 2 upon approval by the medical monitor)\n* Life expectancy of greater than or equal to (>/=) 3 months\n* Disease-free of active second/secondary or prior malignancies >/= 2 years with the exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma \"in-situ\" of the cervix or breast\n* Adequate hematological, renal, hepatic and coagulation laboratory test results\n* Women of child bearing potential and men must agree to use adequate contraception during the study and for 4 months after the last dose of study drug\n\nAdvanced Solid Malignancies:\n\n* Participants with previously treated, histologically confirmed advanced solid malignancy with progressive disease requiring therapy\n* Participants must be refractory or intolerant to standard therapy\n\nNUT-midline carcinoma:\n\n* Participants with histologically confirmed newly diagnosed or relapsed/refractory NMC with PD requiring therapy\n* Diagnosis of one of the following is required:\n\n  1. NUT Midline Carcinoma based on ectopic expression of NUT protein as determined by Immunohistochemistry (IHC) and/or;\n  2. Detection of NUT gene translocation as determined by Fluorescence In-Situ Hybridization (FISH) Advanced Aggressive DLBCL\n* Histologically confirmed advanced aggressive B-cell lymphoma with abnormal MYC expression with persistent disease requiring treatment\n* Participants must have relapsed or progressed after at least 2 lines of prior therapy and not eligible for any curative treatment\n* Participants must have measurable disease\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Participants with hematologic malignancies\n* New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia\n* Have Fridericia-corrected QT interval (QTcF) greater than (>) 470 milliseconds (msec) (female) or > 450 (male), or history of congenital long QT syndrome\n* Active, uncontrolled bacterial, viral, or fungal infections\n* Known clinically important respiratory impairment\n* Positive for human immunodeficiency virus (HIV), hepatitis B surface antigen, or hepatitis C antibodies\n* History of major organ transplant\n* History of an autologous or allogeneic bone marrow transplant. For DLBCL participants only: DLBCL participants may have had a previous autologous transplant but not within 90 days of study entry\n* Symptomatic central nervous system malignancy or metastasis\n* Pregnant or nursing\n* Treatment with surgery or chemotherapy within 28 days prior to study entry\n* Prior treatment with small molecule (BET) family inhibitor\n* Radiation for symptomatic lesions within 14 days of study enrollment",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Participants with solid tumors must have one or more metastatic tumors evaluable or measurable on radiographic imaging",
            "criterions": [
                {
                    "exact_snippets": "solid tumors",
                    "criterion": "solid tumors",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "metastatic tumors evaluable or measurable on radiographic imaging",
                    "criterion": "metastatic tumors",
                    "requirements": [
                        {
                            "requirement_type": "evaluable or measurable",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (or 2 upon approval by the medical monitor)",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (or 2 upon approval by the medical monitor)",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "0",
                                "1",
                                "2 upon approval by the medical monitor"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy of greater than or equal to (>/=) 3 months",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of greater than or equal to (>/=) 3 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Disease-free of active second/secondary or prior malignancies >/= 2 years with the exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma \"in-situ\" of the cervix or breast",
            "criterions": [
                {
                    "exact_snippets": "Disease-free of active second/secondary or prior malignancies >/= 2 years",
                    "criterion": "active second/secondary or prior malignancies",
                    "requirements": [
                        {
                            "requirement_type": "disease-free duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma \"in-situ\" of the cervix or breast",
                    "criterion": "currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma \"in-situ\" of the cervix or breast",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hematological, renal, hepatic and coagulation laboratory test results",
            "criterions": [
                {
                    "exact_snippets": "Adequate hematological ... laboratory test results",
                    "criterion": "hematological laboratory test results",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... renal ... laboratory test results",
                    "criterion": "renal laboratory test results",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... hepatic ... laboratory test results",
                    "criterion": "hepatic laboratory test results",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... coagulation laboratory test results",
                    "criterion": "coagulation laboratory test results",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of child bearing potential and men must agree to use adequate contraception during the study and for 4 months after the last dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Women of child bearing potential",
                    "criterion": "women of child bearing potential",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "men must agree to use adequate contraception",
                    "criterion": "men contraception agreement",
                    "requirements": [
                        {
                            "requirement_type": "agreement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Women of child bearing potential and men must agree to use adequate contraception during the study and for 4 months after the last dose of study drug",
                    "criterion": "contraception duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": "during the study and for 4 months after the last dose of study drug"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Advanced Solid Malignancies:",
            "criterions": [
                {
                    "exact_snippets": "Advanced Solid Malignancies",
                    "criterion": "solid malignancies",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "advanced"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with previously treated, histologically confirmed advanced solid malignancy with progressive disease requiring therapy",
            "criterions": [
                {
                    "exact_snippets": "previously treated",
                    "criterion": "treatment history",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "previously treated"
                        }
                    ]
                },
                {
                    "exact_snippets": "histologically confirmed",
                    "criterion": "diagnosis confirmation",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": "histologically confirmed"
                        }
                    ]
                },
                {
                    "exact_snippets": "advanced solid malignancy",
                    "criterion": "cancer type",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "advanced"
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": "solid malignancy"
                        }
                    ]
                },
                {
                    "exact_snippets": "progressive disease",
                    "criterion": "disease progression",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "progressive"
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring therapy",
                    "criterion": "treatment necessity",
                    "requirements": [
                        {
                            "requirement_type": "necessity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must be refractory or intolerant to standard therapy",
            "criterions": [
                {
                    "exact_snippets": "refractory ... to standard therapy",
                    "criterion": "refractory to standard therapy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "intolerant to standard therapy",
                    "criterion": "intolerant to standard therapy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "NUT-midline carcinoma:",
            "criterions": [
                {
                    "exact_snippets": "NUT-midline carcinoma",
                    "criterion": "NUT-midline carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with histologically confirmed newly diagnosed or relapsed/refractory NMC with PD requiring therapy",
            "criterions": [
                {
                    "exact_snippets": "histologically confirmed newly diagnosed or relapsed/refractory NMC",
                    "criterion": "NMC diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "newly diagnosed",
                                "relapsed/refractory"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "PD requiring therapy",
                    "criterion": "PD",
                    "requirements": [
                        {
                            "requirement_type": "treatment necessity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of one of the following is required:",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of one of the following is required",
                    "criterion": "diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. NUT Midline Carcinoma based on ectopic expression of NUT protein as determined by Immunohistochemistry (IHC) and/or;",
            "criterions": [
                {
                    "exact_snippets": "NUT Midline Carcinoma based on ectopic expression of NUT protein",
                    "criterion": "NUT Midline Carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "expression",
                            "expected_value": "ectopic"
                        }
                    ]
                },
                {
                    "exact_snippets": "NUT protein as determined by Immunohistochemistry (IHC)",
                    "criterion": "NUT protein",
                    "requirements": [
                        {
                            "requirement_type": "determination method",
                            "expected_value": "Immunohistochemistry (IHC)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Detection of NUT gene translocation as determined by Fluorescence In-Situ Hybridization (FISH) Advanced Aggressive DLBCL",
            "criterions": [
                {
                    "exact_snippets": "Detection of NUT gene translocation",
                    "criterion": "NUT gene translocation",
                    "requirements": [
                        {
                            "requirement_type": "detection",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Advanced Aggressive DLBCL",
                    "criterion": "Advanced Aggressive DLBCL",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed advanced aggressive B-cell lymphoma with abnormal MYC expression with persistent disease requiring treatment",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed advanced aggressive B-cell lymphoma",
                    "criterion": "B-cell lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": "histologically confirmed"
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": "advanced"
                        },
                        {
                            "requirement_type": "aggressiveness",
                            "expected_value": "aggressive"
                        }
                    ]
                },
                {
                    "exact_snippets": "abnormal MYC expression",
                    "criterion": "MYC expression",
                    "requirements": [
                        {
                            "requirement_type": "expression status",
                            "expected_value": "abnormal"
                        }
                    ]
                },
                {
                    "exact_snippets": "persistent disease requiring treatment",
                    "criterion": "disease persistence",
                    "requirements": [
                        {
                            "requirement_type": "persistence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have relapsed or progressed after at least 2 lines of prior therapy and not eligible for any curative treatment",
            "criterions": [
                {
                    "exact_snippets": "relapsed or progressed",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "relapsed",
                                "progressed"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "after at least 2 lines of prior therapy",
                    "criterion": "prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "lines"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "not eligible for any curative treatment",
                    "criterion": "curative treatment eligibility",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have measurable disease",
            "criterions": [
                {
                    "exact_snippets": "Participants must have measurable disease",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "volunteer health status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "healthy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Participants with hematologic malignancies",
            "criterions": [
                {
                    "exact_snippets": "hematologic malignancies",
                    "criterion": "hematologic malignancies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia",
            "criterions": [
                {
                    "exact_snippets": "New York Heart Association Class III or IV",
                    "criterion": "New York Heart Association class",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "cardiac disease",
                    "criterion": "cardiac disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction within the past 6 months",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable arrhythmia",
                    "criterion": "unstable arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have Fridericia-corrected QT interval (QTcF) greater than (>) 470 milliseconds (msec) (female) or > 450 (male), or history of congenital long QT syndrome",
            "criterions": [
                {
                    "exact_snippets": "Fridericia-corrected QT interval (QTcF) greater than (>) 470 milliseconds (msec) (female)",
                    "criterion": "Fridericia-corrected QT interval (QTcF)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 470,
                                "unit": "milliseconds"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Fridericia-corrected QT interval (QTcF) ... > 450 (male)",
                    "criterion": "Fridericia-corrected QT interval (QTcF)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 450,
                                "unit": "milliseconds"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "history of congenital long QT syndrome",
                    "criterion": "congenital long QT syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active, uncontrolled bacterial, viral, or fungal infections",
            "criterions": [
                {
                    "exact_snippets": "Active, uncontrolled bacterial ... infections",
                    "criterion": "bacterial infections",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "Active, uncontrolled ... viral ... infections",
                    "criterion": "viral infections",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "Active, uncontrolled ... fungal infections",
                    "criterion": "fungal infections",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known clinically important respiratory impairment",
            "criterions": [
                {
                    "exact_snippets": "Known clinically important respiratory impairment",
                    "criterion": "respiratory impairment",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "clinically important"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Positive for human immunodeficiency virus (HIV), hepatitis B surface antigen, or hepatitis C antibodies",
            "criterions": [
                {
                    "exact_snippets": "Positive for human immunodeficiency virus (HIV)",
                    "criterion": "HIV status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Positive for ... hepatitis B surface antigen",
                    "criterion": "hepatitis B surface antigen",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Positive for ... hepatitis C antibodies",
                    "criterion": "hepatitis C antibodies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of major organ transplant",
            "criterions": [
                {
                    "exact_snippets": "History of major organ transplant",
                    "criterion": "major organ transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of an autologous or allogeneic bone marrow transplant. For DLBCL participants only: DLBCL participants may have had a previous autologous transplant but not within 90 days of study entry",
            "criterions": [
                {
                    "exact_snippets": "History of an autologous or allogeneic bone marrow transplant",
                    "criterion": "bone marrow transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "DLBCL participants may have had a previous autologous transplant",
                    "criterion": "autologous transplant for DLBCL participants",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "not within 90 days of study entry",
                    "criterion": "autologous transplant timing for DLBCL participants",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": ">",
                                "value": 90,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Symptomatic central nervous system malignancy or metastasis",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic central nervous system malignancy",
                    "criterion": "central nervous system malignancy",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Symptomatic ... metastasis",
                    "criterion": "metastasis",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant or nursing",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "nursing",
                    "criterion": "nursing status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with surgery or chemotherapy within 28 days prior to study entry",
            "criterions": [
                {
                    "exact_snippets": "Treatment with surgery ... within 28 days prior to study entry",
                    "criterion": "surgery treatment",
                    "requirements": [
                        {
                            "requirement_type": "time since treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Treatment with ... chemotherapy within 28 days prior to study entry",
                    "criterion": "chemotherapy treatment",
                    "requirements": [
                        {
                            "requirement_type": "time since treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with small molecule (BET) family inhibitor",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with small molecule (BET) family inhibitor",
                    "criterion": "prior treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment type",
                            "expected_value": "small molecule (BET) family inhibitor"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiation for symptomatic lesions within 14 days of study enrollment",
            "criterions": [
                {
                    "exact_snippets": "Radiation for symptomatic lesions within 14 days of study enrollment",
                    "criterion": "radiation for symptomatic lesions",
                    "requirements": [
                        {
                            "requirement_type": "time since treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "General:",
            "criterions": []
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}